Kidney Cancer (Renal Cell Cancer) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Kidney Cancer (Renal Cell Cancer) – Pipeline Review, H2 2017’, provides an overview of the Kidney Cancer (Renal Cell Cancer) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Kidney Cancer (Renal Cell Cancer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Kidney Cancer (Renal Cell Cancer) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Kidney Cancer (Renal Cell Cancer)

The report reviews pipeline therapeutics for Kidney Cancer (Renal Cell Cancer) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Kidney Cancer (Renal Cell Cancer) therapeutics and enlists all their major and minor projects

The report assesses Kidney Cancer (Renal Cell Cancer) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Kidney Cancer (Renal Cell Cancer)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Kidney Cancer (Renal Cell Cancer)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Kidney Cancer (Renal Cell Cancer) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4SC AG

Aadi Bioscience Inc

AbbVie Inc

Actuate Therapeutics Inc

Adaptimmune Therapeutics Plc

Aduro BioTech Inc

Advanced Cancer Therapeutics LLC

Advenchen Laboratories LLC

Affitech A/S

Alethia Biotherapeutics Inc

Alkermes Plc

Altor BioScience Corp

Ambrx Inc

Amgen Inc

Ampio Pharmaceuticals Inc

Apac Biotech Pvt Ltd

Apcure SAS

APEIRON Biologics AG

Aphios Corp

arGEN-X BV

Argos Therapeutics Inc

ARMO Biosciences Inc

ArQule Inc

Arrowhead Pharmaceuticals Inc

Astellas Pharma Inc

AstraZeneca Plc

Bayer AG

BeiGene Ltd

Bio-Cancer Treatment International Ltd

Biocad

Biohaven Pharmaceutical Holding Company Ltd

Bionomics Ltd

Bionovis SA

Biotest AG

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Calithera Biosciences Inc

CASI Pharmaceuticals Inc

CBT Pharmaceuticals Inc

Celgene Corp

Celldex Therapeutics Inc

Cellectar Biosciences Inc

Cellular Biomedicine Group Inc

Celyad SA

Checkpoint Therapeutics Inc

Chipscreen Biosciences Ltd

Cleave Biosciences Inc

Cleveland BioLabs Inc

Clovis Oncology Inc

COARE Biotechnology Inc

Coherus BioSciences Inc

Corvus Pharmaceuticals Inc

Dr. Reddy's Laboratories Ltd

Ecrins Therapeutics SAS

Eisai Co Ltd

Eli Lilly and Co

Esperance Pharmaceuticals Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Gene Techno Science Co Ltd

Genentech Inc

Genor BioPharma Co Ltd

GlaxoSmithKline Plc

Glycotope GmbH

Hemispherx Biopharma Inc

HitGen LTD

Horizon Pharma Plc

Hutchison MediPharma Ltd

Ignyta Inc

Ildong Pharmaceutical Co Ltd

Immune Design Corp

Immune Pharmaceuticals Inc

Immunicum AB

ImmunoFrontier Inc

ImmunoGen Inc

Immunomedics Inc

Immunomet Therapeutics Inc

Incyte Corp

Innovation Pharmaceuticals Inc

Inovio Pharmaceuticals Inc

Inspyr Therapeutics Inc

Johnson & Johnson

KAHR medical Ltd

Karyopharm Therapeutics Inc

KineMed Inc

Kite Pharma Inc

Konruns Pharmaceutical Co Ltd

Kyowa Hakko Kirin Co Ltd

Lead Discovery Center GmbH

Lidds AB

Lycera Corp

MacroGenics Inc

Madrigal Pharmaceuticals Inc.

Mantis Therapeutics BV

MaxiVAX SA

MedImmune LLC

Medinet Co Ltd

Merck & Co Inc

Merck KGaA

Merrimack Pharmaceuticals Inc

Mersana Therapeutics Inc

Millennium Pharmaceuticals Inc

Mirati Therapeutics Inc

Moderna Therapeutics Inc

Molecular Partners AG

Moleculin Biotech Inc

Mologen AG

Monopar Therapeutics LLC

Mycenax Biotech Inc

NantKwest Inc

NBE-Therapeutics AG

Nektar Therapeutics

NewLink Genetics Corp

Novartis AG

NovaTarg Therapeutics Inc

Omeros Corp

OncBioMune Pharmaceuticals Inc

Oncobiologics Inc

Oncolys BioPharma Inc

OncoMax

OncoTherapy Science Inc

Oncovir Inc

Ono Pharmaceutical Co Ltd

Peloton Therapeutics Inc

Pfizer Inc

Pharma Mar SA

Pharmicell Co Ltd

Pivotal BioSciences Inc

Plexxikon Inc

PsiOxus Therapeutics Ltd

Regeneron Pharmaceuticals Inc

Rexahn Pharmaceuticals Inc

Richter Gedeon Nyrt

Sanofi

Selvita SA

Sevion Therapeutics Inc

Shionogi & Co Ltd

Sillajen Biotherapeutics

Sorrento Therapeutics Inc

Sumitomo Dainippon Pharma Co Ltd

Sun Pharma Advanced Research Company Ltd

Syndax Pharmaceuticals Inc

Synthon Holdings BV

Systimmune Inc

Taiwan Liposome Company Ltd

Taris Biomedical LLC

TC BioPharm Ltd

Tesaro Inc

Tocagen Inc

Tolero Pharmaceuticals Inc

TRACON Pharmaceuticals Inc

TVAX Biomedical Inc

Tyrogenex Inc

UroGen Pharmaceuticals Ltd

Vaccibody AS

Vascular Biogenics Ltd

Vault Pharma Inc

Vaxeal Holding SA

ViiV Healthcare UK Ltd

Vyriad Inc

X4 Pharmaceuticals Inc

Xspray Pharma AB

Table of Contents

Table of Contents

Table of Contents 2

Introduction 8

Kidney Cancer (Renal Cell Cancer) Overview 9

Kidney Cancer (Renal Cell Cancer) Therapeutics Development 10

Kidney Cancer (Renal Cell Cancer) Therapeutics Assessment 49

Kidney Cancer (Renal Cell Cancer) Companies Involved in Therapeutics Development 73

Kidney Cancer (Renal Cell Cancer) Drug Profiles 152

Kidney Cancer (Renal Cell Cancer) Dormant Projects 1368

Kidney Cancer (Renal Cell Cancer) Discontinued Products 1383

Kidney Cancer (Renal Cell Cancer) Product Development Milestones 1387

Appendix 1402

List of Tables

List of Tables

Number of Products under Development for Kidney Cancer (Renal Cell Cancer), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..8), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..9), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..10), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Products under Development by Companies, H2 2017 (Contd..5), H2 2017

Products under Development by Companies, H2 2017 (Contd..6), H2 2017

Products under Development by Companies, H2 2017 (Contd..7), H2 2017

Products under Development by Companies, H2 2017 (Contd..8), H2 2017

Products under Development by Companies, H2 2017 (Contd..9), H2 2017

Products under Development by Companies, H2 2017 (Contd..10), H2 2017

Products under Development by Companies, H2 2017 (Contd..11), H2 2017

Products under Development by Companies, H2 2017 (Contd..12), H2 2017

Products under Development by Companies, H2 2017 (Contd..13), H2 2017

Products under Development by Companies, H2 2017 (Contd..14), H2 2017

Products under Development by Companies, H2 2017 (Contd..15), H2 2017

Products under Development by Companies, H2 2017 (Contd..16), H2 2017

Products under Development by Companies, H2 2017 (Contd..17), H2 2017

Products under Development by Companies, H2 2017 (Contd..18), H2 2017

Products under Development by Companies, H2 2017 (Contd..19), H2 2017

Products under Development by Companies, H2 2017 (Contd..20), H2 2017

Products under Development by Universities/Institutes, H2 2017

Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..5), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..6), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..7), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..8), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..5), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..6), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..7), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..8), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Kidney Cancer (Renal Cell Cancer) Pipeline by 4SC AG, H2 2017

Kidney Cancer (Renal Cell Cancer) Pipeline by Aadi Bioscience Inc, H2 2017

Kidney Cancer (Renal Cell Cancer) Pipeline by AbbVie Inc, H2 2017

Kidney Cancer (Renal Cell Cancer) Pipeline by Actuate Therapeutics Inc, H2 2017

Kidney Cancer (Renal Cell Cancer) Pipeline by Adaptimmune Therapeutics Plc, H2 2017

Kidney Cancer (Renal Cell Cancer) Pipeline by Aduro BioTech Inc, H2 2017

Kidney Cancer (Renal Cell Cancer) Pipeline by Advanced Cancer Therapeutics LLC, H2 2017

Kidney Cancer (Renal Cell Cancer) Pipeline by Advenchen Laboratories LLC, H2 2017

Kidney Cancer (Renal Cell Cancer) Pipeline by Affitech A/S, H2 2017

Kidney Cancer (Renal Cell Cancer) Pipeline by Alethia Biotherapeutics Inc, H2 2017

Kidney Cancer (Renal Cell Cancer) Pipeline by Alkermes Plc, H2 2017

Kidney Cancer (Renal Cell Cancer) Pipeline by Altor BioScience Corp, H2 2017

Kidney Cancer (Renal Cell Cancer) Pipeline by Ambrx Inc, H2 2017

Kidney Cancer (Renal Cell Cancer) Pipeline by Amgen Inc, H2 2017

Kidney Cancer (Renal Cell Cancer) Pipeline by Ampio Pharmaceuticals Inc, H2 2017

Kidney Cancer (Renal Cell Cancer) Pipeline by Apac Biotech Pvt Ltd, H2 2017

Kidney Cancer (Renal Cell Cancer) Pipeline by Apcure SAS, H2 2017

List of Figures

List of Figures

Number of Products under Development for Kidney Cancer (Renal Cell Cancer), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports